HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study.

AbstractPURPOSE:
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix.
METHODS:
PZA was administered at a dose of 750 mg/m2 intravenously over three hours every three weeks.
RESULTS:
Among 21 evaluable patients, there were no complete and one (4.2%) partial response. The major toxicities were hematologic.
CONCLUSION:
PZA at the dose and schedule employed has insignificant activity in this population.
AuthorsS C Plaxe, J A Blessing, J A Lucci, J A Hurteau
JournalInvestigational new drugs (Invest New Drugs) Vol. 19 Issue 1 Pg. 77-80 ( 2001) ISSN: 0167-6997 [Print] United States
PMID11291835 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Acridines
  • Antineoplastic Agents
  • Pyrazoles
  • NSC 366140
Topics
  • Acridines (administration & dosage, adverse effects, therapeutic use)
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, pathology)
  • Female
  • Humans
  • Middle Aged
  • Pyrazoles (administration & dosage, adverse effects, therapeutic use)
  • Treatment Outcome
  • Uterine Cervical Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: